leadf
logo-loader
LSE:DDDD

4D pharma plc

Receive alerts
Market:
LSE
Market Cap:
£175.41 m
Price
133.50 GBX
Change
16.09%
52 weeks high
183.00
52 weeks low
23.50

We understand that bacteria in the human intestine - known as the gut microbiome - have an important function in many diseases.

Importantly, we understand how they function and how they could be used as a revolutionary new class of medicines known as Live Biotherapeutics.

Our deep understanding of bacterial functionality enables us to develop Live Biotherapeutics for a large number of diseases including cancer, gastrointestinal disease, respiratory disease and central nervous system disease.

What makes 4D pharma different?

We understand that the bacteria of the gut microbiome have an important function in health and disease, but importantly – we understand how they function, and how they could be used as potential new therapies.

4D and the Live Biotherapeutics we develop have the potential to transform he way in which many challenging diseases are treated.

What sets us apart?

We are targeting a new, safer approach to drug development

We are a fully integrated microbiome company with the capability to progress from research to production to clinic

We understand mechanism: how our products exert their therapeutic effects and act as a drug

We have developed and wholly own the largest intellectual property estate in the field

We have laid foundations that have positioned 4D to transform the sector; with four clinical programmes set to deliver data and a number of development programmes heading towards the clinic, 4D will play the lead role in defining the microbiome space.

To read more, click here.

Collaborations

MSD, a tradename of Merck & Co., Inc.

Global healthcare company

https://www.merck.com/index.html

Kenilworth, NJ, USA

 

University of Texas MD Anderson Cancer Center

World-leading cancer research centre

https://www.mdanderson.org/

Houston, TX, USA

Axel Glasmacher - Non-Executive Chairperson

Professor Dr. med. Axel Glasmacher was until recently Senior Vice President and Head of the Clinical Research and Development Hematology Oncology at Celgene, where he has worked in various global roles for more than ten years. His work at Celgene led to the approvals of Revlimid®, Idhifa® and Vidaza® (haematological cancers). He also worked on the PD-L1 inhibitor durvalumab. Prior to Celgene, Professor Glasmacher worked within the fields of haematology-oncology at the University Hospital in Bonn.

 

Duncan Peyton - Chief Executive Officer

Duncan has a proven track record in identifying, investing in and growing businesses within the pharmaceutical sector. He was the founder of Aquarius Equity, a specialist investor in businesses within the life sciences sector, which provided investors with access to innovative, high growth potential companies that delivered significant capital growth. Duncan started his career in a bio-science start-up business, which ultimately went on to list on the London Stock Exchange, subsequently qualified as a corporate finance lawyer with Addleshaw Goddard, then Addleshaw Booth & Co, and later joined 3i plc as an investment manager. Duncan founded Aquarius in 2005, which made founding investments into Nanoco Technologies Limited, Auralis Limited (subsequently sold to ViroPharma), Tissue Regenix Group plc, Brabant Pharma (subsequently sold to Zogenix, Inc and C4X Discovery plc. Duncan is a co-founder of 4D pharma plc and has served as Chief Executive Officer since 2014.

 

Alex Stevenson - Chief Scientific Officer

Alex began his career as a microbiologist, working in research for a number of years before joining an NYSE-quoted drug development company. He subsequently moved into pharmaceutical and healthcare investment and has fulfilled a number of board-level investment and operational management roles. He was a director and shareholder in Aquarius Equity from 2008, where he was responsible for identifying new investments and developing and implementing scientific strategies both pre and post-investment. These included Tissue Regenix Group plc, C4X Discovery Holdings plc and Brabant Pharma (subsequently sold to Zogenix, Inc.). Prior to joining Aquarius Equity, Alex worked for IP Group plc, where he specialised in life sciences investments identifying, developing and advising a number of companies in its portfolio, some of which went on to list on AIM. He joined IP Group following its acquisition of Techtran Group Limited in 2005. Alex is a co-founder of 4D pharma plc and has served as Chief Scientific Officer since 2014.

 

David Norwood - Non-Executive Director

David has had a long career building a number of science, technology and investment companies. He is the founder of IP Group plc, one of the UK’s leading technology commercialisation businesses, and a shareholder in the Company. Previously, he was chief executive of stockbroker Beeson Gregory (acquired by Evolution Group plc) after it acquired IndexIT Partnership, a technology advisory boutique he had founded in 1999. He was a founding shareholder of Evolution Group plc (acquired by Investec), and also co-founder of Ora Capital plc. He has been a founder and director of many UK technology companies including Oxford Nanopore Technologies Limited, Proximagen Limited, Synairgen plc, Ilika Technologies Limited, Oxford Catalysts and Plectrum Petroleum (acquired by Cairn Energy plc). He has also acted as seed investor and/or advisor to Wolfson Microelectronics Limited, Nanoco Technologies Limited, Tissue Regenix Group plc and Arc International (now part of Synopsys). He is also non-executive chairman of Oxford Pharmascience Group plc., Abaco Capital plc and Genomics plc.

 

Ed Baracchini - Non-Executive Director

Ed Baracchini has had a long and successful career in the pharmaceutical industry. He currently serves of the Board of Directors of INmune Bio, Inc. He was previously the Chief Business Officer at Xencor Inc. where he lead strategic alliances and licensing. During his time at Xencor he negotiated licence agreements with Novartis ($2.6 billion: immuno-oncology bispecific antibodies) , Novo Nordisk ($600 million: drug discovery collaboration), Amgen ($500 million: option and development agreement autoimmune disease antibody) among numerous others. Prior to that he served as SVP Business Development for Metabasis Therapeutics.

 

Sandy Macrae - Non-Executive Director

Dr. Sandy Macrae has over twenty years of experience in the pharmaceutical industry, with a combination of scientific, medical and commercial expertise. Dr. Macrae currently serves as President and Chief Executive Officer of Sangamo Therapeutics, Inc. (“Sangamo”; NASDAQ: SGMO), a leading genomic medicine company active in developing cell and gene therapies across a range of rare and large indications.

Dr. Macrae has previously served as Global Medical Officer of Takeda Pharmaceuticals, overseeing medical affairs, regulatory affairs, pharmacovigilance, outcomes research and epidemiology, quantitative sciences, and knowledge and informatics. Prior to that, Dr. Macrae held roles of increasing responsibility at GlaxoSmithKline, including Senior Vice President, Emerging Markets Research and Development (R&D), and Vice President, Business Development. Earlier in his career, he worked for SmithKline Beecham, where he was responsible for clinical development in the therapeutic areas of neurology and gastroenterology.

 

Board Committees

The Audit and Risk Committee is comprised of David Norwood and Ed Baracchini

The Remuneration Committee is comprised of Sandy Macrae and Axel Glasmacher

Head office

4D pharma plc
9 Bond Court
Leeds
LS1 2JZ
United Kingdom

 

General enquiries: [email protected]

Investor relations: [email protected]

Joint broker

Bryan Garnier & Co. Limited

Beaufort House

15 St. Botolph Street

London EC3A 7BB

Nominated adviser and joint broker

N+1 Singer
1 Bartholemew Lane
London
EC2N 2AX

Auditor

RSM UK Audit LLP
3 Hardman Street
Manchester M3 3HF

 

Registrar

Link Asset Services
The Registry
34 Beckenham Road
Beckenham
Kent BR3 4TU